News - Boehringer Ingelheim


Current filters:

Boehringer Ingelheim

Popular Filters

37 to 61 of 167 results

Pradaxa sNDA for DVT and PE accepted by FDA


The US Food and Drug Administration has accepted for review German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Gilotrif to debut in the USA in week starting Sept 2


The US subsidiary of family-owned German drug major Boehringer Ingelheim says that, following last month's…

Boehringer IngelheimGilotrifMarkets & MarketingNorth AmericaOncologyPharmaceutical

Positive Ph III data for Trajenta in elderly type 2 diabetes patients


Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4)…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

Boehringer Ingelheim remains on growth path, despite difficult scenario


Family-owned German drug major Boehringer Ingelheim says it grew further in the first half of 2013, despite…

Boehringer IngelheimFinancialPharmaceutical

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline


German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

Polyphor-Boehringer Ingelheim alliance moves forward


Privately-held Swiss biotechnology company Polyphor has entered into the next stage of its drug discovery…

BiotechnologyBoehringer IngelheimEuropePolyphorResearch

Boehringer Ingelheim and Eli Lilly launch linagliptin trial


German family-owned drug major Boehringer Ingelheim and US pharma major Eli Lilly (NYSE: LLY) have enrolled…

Boehringer IngelheimDiabetesEli LillyEuropelinagliptinPharmaceuticalResearch

Germany's Bayer and Boehringer both get CHMP backing


Among a string of positive recommendations revealed last Friday (July 26) by the European Medicines Agency's…

afatinibBayerBoehringer IngelheimEuropeEyleaGiotrifOncologyOphthalmicsPharmaceuticalRegulation

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs


Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

Boehringer Ingelheim's Gilotrif could be leading therapy if it overcomes concerns, says GlobalData


Family-owned German drug major Boehringer Ingelheim could face "significant challenges" over its first-line…

AstraZenecaBoehringer IngelheimEuropeGilotrifIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

US FDA approves Boehringer Ingelheim's first cancer drug


In what the family-owned German drug major Boehringer Ingelheim hopes is just the first drug to come…

afatinibBiotechnologyBoehringer IngelheimGilotrifNorth AmericaOncologyPharmaceuticalQiagenRegulation

AstraZeneca in oncology partnerships with University of Cambridge, Cancer Research UK and Blackfield


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reached agreement with the University of Cambridge…

AstraZenecaBlackfieldBoehringer IngelheimJanssenMerck KGaAolaparibOncologyPharmaceuticalResearch

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA


US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

Pharma giants included in China's investigation into pricing of foreign imports


China's National Development and Reform Commission (NDRC) has launched an investigation into UK pharma…

Astellas PharmaBaxterBoehringer IngelheimGlaxoSmithKlineJiangsu Hengrui MedicinePharmaceuticalPricingRegulationSandozSinopharm Group

FDA approves Boehringer and Lilly's Tradjenta and Jentadueto labeling to reflect pancreatitis risk


German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June…

Boehringer IngelheimDiabetesEli LillyJentaduetoNorth AmericaPharmaceuticalRegulationTradjenta

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis


Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered into an…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularKarolinska DevelopmentLicensing

Boehringer Ingelheim's all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C


New data from German family-owned drug major Boehringer Ingelheim's interferon-free SOUND-C3, presented…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalResearch

Boehringer Ingelheim to build biopharma facility in China


German family-owned drug major Boehringer Ingelheim has signed a strategic alliance agreement and contract…

Asia-PacificBiotechnologyBoehringer IngelheimFinancialPharmaceuticalProductionShanghai Zhangjiang Biotech

37 to 61 of 167 results

Back to top